TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05067777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Receive SMT
Study: NCT05530512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture needling and stimulation are applied for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture needling and stimulation are applied for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture needling and stimulation are applied for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture needling and stimulation are applied for 30 min
Study: NCT06512909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses Application
Description: A video containing relaxing nature images will be shown to a group via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball Application
Description: One group will be given a stress ball in the hand on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, intramuscular injection will begin and the procedure will be performed while squeezing the ball.
Study: NCT05496920

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FD-PET/CT
Description: Standard of care PET/CT with full dose (FD) of the radiopharmaceutical

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LD-PET/CT
Description: Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
Study: NCT05221554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-navigated THA surgery
Description: Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care THA surgery
Description: Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
Study: NCT05067777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04620603

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Rate Brachytherapy (LDR)
Description: LDR on treatment day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-Care Immunotherapy
Description: Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
Study: NCT05067777

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Receive light touch control procedure
Study: NCT06039306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition oral nutrition supplementation
Description: Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
Study: NCT06474936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food education
Description: During the consultations are planned at least 6 nutritional education sessions in which the general nutritional advice provided by the Mediterranean Diet will be exposed, and some paper materials can be delivered according to the needs of each individual. 3 in-person meetings and 3 online meetings are planned. Both online and in-person food education sessions will be conducted by experienced nutrition experts monthly. These sessions will cover a range of topics, including the principles of the Mediterranean diet, practical cooking skills, meal-planning strategies, and tips for incorporating Mediterranean-style dishes into daily life
Study: NCT06338761

Intervention type: BEHAVIORAL
Intervention: Smoking cessation
Description: Stop smoking

Intervention type: BEHAVIORAL
Intervention: Switching to E-cigarette
Description: Switching to E-cigarette
Study: NCT05635838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study: NCT05634512

Intervention type: DRUG
Intervention: Laronidase therapy and a stem cell transplant
Description: To identify key differences leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH. There will be 12 samples per patient (6 pre-transplant and 6-post-transplant). Laronidase will be administered IV per protocol using standard dosing (0.58 mg/kg intravenously on a weekly basis), and six (n=6) blood samples will be collected over 24 hours for the determination of mononuclear cell lysates and plasma laronidase concentrations for a total of 18mL. The second PK monitoring will be obtained using the same PK design but following complete or near-completedonor derived myeloid engraftment which is evaluated at different time pointspost-HCT (day 30, day 42, day 60). The standard is to continue ERT through 8 weeks post-transplant.
Study: NCT05523635

Intervention type: DEVICE
Intervention: Gamma4 Nailing System
Description: The Gamma4 Nailing System is is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
Study: NCT05415280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based stress reduction
Description: The aim of the psychological intervention to reduce the mental health problems of the participants.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based stress reduction
Description: The aim of the psychological intervention to reduce the mental health problems of the participants.
Study: NCT05860231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-Control catheter
Description: The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
Study: NCT05020444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TriPRIL CAR T Cells
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TriPRIL CAR T Cells
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion
Study: NCT05636254

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Brain and spine
Description: * MRI Brain~* Ax T2 TSE~* 3D Sag T1~* Ax DWI~* 3D Sag Flair~* Ax SWI~* Post-gad 3D Sag T1~* 3D TOF Circle-of-Willis~* MRI Spine~* Sag T2 whole spine (2 stations)~* Post-gad Sag T1 whole spine (2 stations)
Study: NCT05374941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable and wearable neurostimulator for the hypoglossal nerve
Description: Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable and wearable neurostimulator for the hypoglossal nerve
Description: Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
Study: NCT05615714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paresthesia-free Peripheral Nerve Field Stimulation
Description: High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Stimulation will be turned off.
Study: NCT05261451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
Study: NCT05636254

Intervention type: DIAGNOSTIC_TEST
Intervention: Reference standard diagnostic criteria
Description: Diagnostic criteria-TBM~* Microbiologic evidence of TB in CSF~* Microbiologic evidence of TB from pulmonary or extrapulmonary sites~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~* Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~* Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis
Study: NCT06492109

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental sleep deprivation
Description: Cognitive assessment of subjects: This study will collect the Mini-Mental State Examination (MMSE) results as a supplement to the Montreal Cognitive Assessment (MoCA). The sleep status of subjects will be screened using the Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). Subjects must maintain regular sleep and diet before sample collection. Peripheral blood samples will be taken the day before, the day of, and the day after acute sleep deprivation, whether voluntary or involuntary, along with anxiety and depression assessments. For chronic sleep deprivation (≥7 days), blood samples will be collected before and after the deprivation period, with anxiety, depression, and cognitive assessments. Voluntary sleep deprivation occurs under experimental conditions, while involuntary deprivation is due to factors like age or shift work.
Study: NCT05762705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel Gaming Adherence Intervention
Description: Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual +
Description: non-PrEP related mobile gaming application
Study: NCT06449690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy
Description: Dog-assisted therapy consists of the search for positive interactions resulting from the intentional human-animal relationship in the educational, therapeutic or social fields, practices as they are conducted in educational and medico-social institutions for example.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occupational activities
Description: Occupational activities consist of origami, relaxation, sports or board games sessions.
Study: NCT06103552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Lifestyle Options for Orthopedic Mobility (BLOOM)
Description: This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
Study: NCT05601596

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of menstrual blood to predict endometriosis
Description: Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of menstrual blood to predict endometriosis
Description: Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
Study: NCT05140759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automated continual water removal system
Description: The device removes excess fluids in heart failure patients with diuretic resistance
Study: NCT05846139

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PerioTabs® brushing solution
Description: PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine 0.12 %
Description: chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
Study: NCT06300216

Intervention type: DRUG
Intervention: Octreotide microspheres
Description: 20mg/30mg Q4W
Study: NCT05315713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab SC
Description: Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab SC
Description: Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
Study: NCT04930874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS (Near-Infrared Spectroscopy)
Description: NIRS assessment of cerebral autoregulation and cerebral blood flow
Study: NCT05198622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection
Description: A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection
Description: A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery.
Study: NCT04815239

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal and Social Rhythm Therapy (IPSRT)
Description: Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Healthy Lifestyle Behavior Intervention (HL)
Description: HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
Study: NCT05143047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication counseling
Description: Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details.
Study: NCT06056115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab,Platinum
Description: 1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy .
Study: NCT05497063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine
Description: Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study: NCT05336370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Description: A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus \[36\]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds \[37\], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session